$RMTG
Regenerative Medical Technology Group Inc.

2024 Q4 Form 10-Q Financial Statement

#000121390024099836 Filed on November 19, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $986.3K
YoY Change 52.48%
Cost Of Revenue $239.2K
YoY Change 21.73%
Gross Profit $747.1K
YoY Change 65.91%
Gross Profit Margin 75.74%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $727.4K
YoY Change 38.46%
Operating Profit $19.65K
YoY Change -126.18%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$906.8K
YoY Change -45.29%
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$887.1K
YoY Change -84.85%
Net Earnings / Revenue -89.95%
Basic Earnings Per Share -$0.07
Diluted Earnings Per Share -$0.07
COMMON SHARES
Basic Shares Outstanding 12.54M shares 12.54M shares
Diluted Shares Outstanding 12.54M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $836.4K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory $6.680K
Prepaid Expenses $43.07K
Receivables
Other Receivables
Total Short-Term Assets $917.2K
YoY Change -22.91%
LONG-TERM ASSETS
Property, Plant & Equipment $349.5K
YoY Change 136.4%
Goodwill $1.680M
YoY Change 0.0%
Intangibles $183.4K
YoY Change -34.72%
Long-Term Investments
YoY Change
Other Assets $7.264K
YoY Change 30.41%
Total Long-Term Assets $2.311M
YoY Change 8.75%
TOTAL ASSETS
Total Short-Term Assets $917.2K
Total Long-Term Assets $2.311M
Total Assets $3.228M
YoY Change -2.61%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.103M
YoY Change 200.43%
Accrued Expenses $8.898M
YoY Change 25.67%
Deferred Revenue $79.85K
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $27.49M
YoY Change 12.53%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $27.49M
Total Long-Term Liabilities
Total Liabilities $29.95M
YoY Change 20.49%
SHAREHOLDERS EQUITY
Retained Earnings -$66.91M
YoY Change 8.39%
Common Stock $12.54K
YoY Change 0.76%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$26.72M
YoY Change
Total Liabilities & Shareholders Equity $3.228M
YoY Change -2.61%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$887.1K
YoY Change -84.85%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Assets Current
AssetsCurrent
574996 usd
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
256544 usd
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
15223519 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
22249135 usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
20500 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
usd
CY2023Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
23956 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
6500000000 shares
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-61990131 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-21795503 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2879103 usd
CY2024Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2714 usd
CY2023Q4 us-gaap Goodwill
Goodwill
1679978 usd
CY2023Q4 us-gaap Assets
Assets
2879103 usd
CY2023Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
2146 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2714 usd
CY2023Q4 mssv Notes Payable Net Of Discount
NotesPayableNetOfDiscount
2382648 usd
CY2023Q4 us-gaap Liabilities
Liabilities
24674605 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-56010
dei Entity Registrant Name
EntityRegistrantName
Regenerative Medical Technology Group Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
88-0492191
dei Entity Address Address Line1
EntityAddressAddressLine1
433 Plaza Real Suite 275
dei Entity Address City Or Town
EntityAddressCityOrTown
Boca Raton
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33432
dei City Area Code
CityAreaCode
(800)
dei Local Phone Number
LocalPhoneNumber
956-3935
dei Security12b Title
Security12bTitle
None
dei No Trading Symbol Flag
NoTradingSymbolFlag
true
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12538968 shares
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
836427 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
530540 usd
CY2024Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
31006 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
6680 usd
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
43067 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
917180 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
349506 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
359303 usd
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
7264 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5568 usd
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
183389 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
90985 usd
CY2024Q3 us-gaap Goodwill
Goodwill
1679978 usd
CY2024Q3 us-gaap Assets
Assets
3228302 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1102903 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
421334 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8897996 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6597422 usd
CY2024Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
79850 usd
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2000 usd
CY2024Q3 us-gaap Derivative Liabilities
DerivativeLiabilities
5574 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
76092 usd
CY2024Q3 us-gaap Notes Payable Current
NotesPayableCurrent
17332250 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
27494664 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
14893 usd
CY2024Q3 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
40758 usd
CY2023Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
35023 usd
CY2024Q3 mssv Notes Payable Net Of Discount
NotesPayableNetOfDiscount
2388674 usd
CY2024Q3 us-gaap Liabilities
Liabilities
29946789 usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
6500000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12538968 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12538968 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12493938 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12493938 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
12539 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
12494 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
40182830 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
40181074 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-66914916 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-26718487 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3228302 usd
CY2024Q3 us-gaap Revenues
Revenues
986308 usd
CY2023Q3 us-gaap Revenues
Revenues
646828 usd
us-gaap Revenues
Revenues
2596671 usd
us-gaap Revenues
Revenues
1794385 usd
CY2024Q3 us-gaap Cost Of Revenue
CostOfRevenue
239247 usd
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
196535 usd
us-gaap Cost Of Revenue
CostOfRevenue
753735 usd
us-gaap Cost Of Revenue
CostOfRevenue
553467 usd
CY2024Q3 us-gaap Gross Profit
GrossProfit
747061 usd
CY2023Q3 us-gaap Gross Profit
GrossProfit
450293 usd
us-gaap Gross Profit
GrossProfit
1842936 usd
us-gaap Gross Profit
GrossProfit
1240918 usd
CY2024Q3 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
94434 usd
CY2023Q3 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
93227 usd
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
335892 usd
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
349675 usd
CY2024Q3 us-gaap Professional Fees
ProfessionalFees
254170 usd
CY2023Q3 us-gaap Professional Fees
ProfessionalFees
161628 usd
us-gaap Professional Fees
ProfessionalFees
755560 usd
us-gaap Professional Fees
ProfessionalFees
626411 usd
CY2024Q3 us-gaap Labor And Related Expense
LaborAndRelatedExpense
22500 usd
CY2023Q3 us-gaap Labor And Related Expense
LaborAndRelatedExpense
22500 usd
us-gaap Labor And Related Expense
LaborAndRelatedExpense
67500 usd
us-gaap Labor And Related Expense
LaborAndRelatedExpense
67500 usd
CY2024Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
88828 usd
CY2023Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
98667 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
248371 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
213170 usd
CY2024Q3 mssv Investor Relation
InvestorRelation
3403 usd
CY2023Q3 mssv Investor Relation
InvestorRelation
2250 usd
mssv Investor Relation
InvestorRelation
49845 usd
mssv Investor Relation
InvestorRelation
6750 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
264077 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
147084 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
685205 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
557527 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
727412 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
525356 usd
us-gaap Operating Expenses
OperatingExpenses
2142373 usd
us-gaap Operating Expenses
OperatingExpenses
1821033 usd
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
905572 usd
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1657600 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
4621920 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
4858406 usd
CY2024Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-1222 usd
CY2023Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
964 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-3428 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
3889 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
2463 usd
CY2023Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
4125460 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
4125460 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-906794 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5782096 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4625348 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-8977514 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-887146 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-5857159 usd
us-gaap Net Income Loss
NetIncomeLoss
-4924786 usd
us-gaap Net Income Loss
NetIncomeLoss
-9557629 usd
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.47
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.47
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.39
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.39
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.77
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.77
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12538968 shares
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12538968 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12443938 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12443938 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12529107 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12529107 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12443938 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12443938 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-21795503 usd
us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
1801 usd
us-gaap Net Income Loss
NetIncomeLoss
-4924786 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-26718487 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-25833142 usd
CY2024Q3 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
1801 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-887146 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-26718487 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-11982292 usd
us-gaap Net Income Loss
NetIncomeLoss
-9557629 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-21539921 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-15682762 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-5857159 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-21539921 usd
us-gaap Net Income Loss
NetIncomeLoss
-4924786 usd
us-gaap Net Income Loss
NetIncomeLoss
-9557629 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
2122293 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
2295758 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
248371 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
213170 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-3428 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
3889 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
2463 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
4125460 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
7050 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-14755 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
22567 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
10750 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
6680 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
1696 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3059992 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2535788 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
471306 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-389800 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
165419 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
101594 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-165419 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-101594 usd
us-gaap Repayments Of Debt
RepaymentsOfDebt
9850 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-9850 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
305886 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-501244 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
530540 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1645185 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
836427 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1143941 usd
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
1801 usd
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
On July 2, 2018, the Board of Directors authorized and shareholders approved a 1-for-1,000 reverse stock split of the Company’s issued and outstanding shares of common stock held by the holders of record.
CY2022Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation
68313 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Use of Estimates in Financial Statement Presentation</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of these financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The significant estimates included in these financial statements are associated with accounting for the goodwill, derivative liability, valuation of preferred stock, and for the valuation of assets and liabilities in business combination.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Reclassifications</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain amounts for the prior year have been revised or reclassified to conform to the current year presentation. No change in net loss resulted from these reclassifications.</p>
CY2024Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2024Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 usd
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
109434563 shares
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
126884881 shares
CY2024Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
5574 usd
CY2024Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
5574 usd
CY2023Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
2146 usd
CY2023Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
2146 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-66914916 usd
CY2024Q3 mssv Working Capital Deficit
WorkingCapitalDeficit
26577484 usd
us-gaap Revenues
Revenues
2596671 usd
us-gaap Revenues
Revenues
1794385 usd
us-gaap Revenues
Revenues
2596671 usd
us-gaap Cost Of Revenue
CostOfRevenue
753735 usd
us-gaap Gross Profit
GrossProfit
1842936 usd
mssv Percentage Of Gross Profit
PercentageOfGrossProfit
0.7097 pure
CY2024Q3 us-gaap Assets
Assets
3228302 usd
us-gaap Net Income Loss
NetIncomeLoss
-4924786 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
7536 usd
CY2023 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
7679 usd
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
0 usd
CY2023 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
9850 usd
CY2019Q4 us-gaap Long Term Debt Term
LongTermDebtTerm
P4Y
CY2019Q4 mssv Promissory Note Premium Interest
PromissoryNotePremiumInterest
0.20 pure
CY2020Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
5379624 usd
CY2020Q4 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
5379624 usd
CY2020Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
15000000 shares
CY2020Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
15000000 shares
CY2024Q3 us-gaap Other Loans Payable
OtherLoansPayable
1999999 usd
CY2023Q4 us-gaap Other Loans Payable
OtherLoansPayable
1999999 usd
CY2020Q4 us-gaap Long Term Debt Term
LongTermDebtTerm
P2Y
CY2021Q1 us-gaap Notes Payable
NotesPayable
1000000 usd
CY2021Q1 us-gaap Long Term Debt Term
LongTermDebtTerm
P1Y
CY2021Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
10000000 shares
CY2021Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.03
CY2021Q1 mssv Advance From Lender
AdvanceFromLender
900000 usd
CY2024Q3 mssv Warrants Issued
WarrantsIssued
10000000 shares
us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
237811 usd
CY2021Q2 us-gaap Notes Payable
NotesPayable
11600000 usd
CY2021Q2 us-gaap Long Term Debt Term
LongTermDebtTerm
P3Y
CY2021Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
70000000 shares
CY2021Q2 mssv Advance From Lender
AdvanceFromLender
10500000 usd
CY2021Q2 mssv Warrants Issued
WarrantsIssued
70000000 shares
CY2021Q2 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
5465726 usd
CY2019Q1 us-gaap Loans And Leases Receivable Gross Carrying Amount
LoansAndLeasesReceivableGrossCarryingAmount
20991 usd
CY2021Q3 us-gaap Notes Payable
NotesPayable
1100000 usd
CY2021Q3 us-gaap Long Term Debt Term
LongTermDebtTerm
P3Y
CY2021Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
7500000 shares
CY2021Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.085
CY2021Q3 mssv Advance From Lender
AdvanceFromLender
1000000 usd
CY2021Q3 mssv Warrants Issued
WarrantsIssued
7500000 shares
CY2021Q3 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
360607 usd
CY2024Q3 us-gaap Notes Payable
NotesPayable
19730731 usd
CY2023Q4 us-gaap Notes Payable
NotesPayable
19730731 usd
CY2020Q4 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
5379624 usd
CY2020Q4 us-gaap Convertible Debt
ConvertibleDebt
5379624 usd
CY2022Q4 us-gaap Derivative Fair Value Of Derivative Net
DerivativeFairValueOfDerivativeNet
6944 usd
CY2023 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
3450 usd
CY2023 mssv Derivative Instruments Conversions
DerivativeInstrumentsConversions
1348 usd
CY2023Q4 us-gaap Derivative Fair Value Of Derivative Net
DerivativeFairValueOfDerivativeNet
2146 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-3428 usd
CY2024Q3 us-gaap Derivative Fair Value Of Derivative Net
DerivativeFairValueOfDerivativeNet
5574 usd
CY2024Q3 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
1000 shares
us-gaap Common Stock Convertible Conversion Price Increase
CommonStockConvertibleConversionPriceIncrease
0.8
CY2022Q1 mssv Monthly Based On Annual Rate
MonthlyBasedOnAnnualRate
90000 usd
us-gaap Other Expenses
OtherExpenses
503552 usd
CY2022Q1 mssv Monthly Based On Annual Rate
MonthlyBasedOnAnnualRate
90000 usd
CY2020Q4 us-gaap Effective Income Tax Rate Reconciliation Disposition Of Assets
EffectiveIncomeTaxRateReconciliationDispositionOfAssets
0.275 pure
us-gaap Payments For Rent
PaymentsForRent
71731 usd
us-gaap Payments For Rent
PaymentsForRent
41164 usd
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
483913 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
308697 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
349506 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
359303 usd
us-gaap Depreciation
Depreciation
175216 usd
us-gaap Depreciation
Depreciation
140015 usd
CY2024Q3 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
487700 usd
CY2023Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
487700 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
304311 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
231156 usd
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
183389 usd
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
256544 usd
CY2024Q3 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P5Y
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
73155 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
73155 usd
CY2021Q4 us-gaap Security Deposit Liability
SecurityDepositLiability
5588 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
19023 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
76092 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
95115 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
4130 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
90985 usd
CY2021Q3 mssv Shares Acquired Percentage
SharesAcquiredPercentage
1 pure
CY2021Q3 us-gaap Cash
Cash
225000 usd
mssv Purchase Price
PurchasePrice
6229000 usd
CY2022Q4 us-gaap Goodwill
Goodwill
5805438 usd
CY2023 us-gaap Goodwill Impairment Loss Net Of Tax
GoodwillImpairmentLossNetOfTax
4125460 usd
CY2023Q4 us-gaap Goodwill
Goodwill
1679978 usd
CY2024Q3 us-gaap Goodwill
Goodwill
1679978 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
4125460 usd
CY2023Q3 us-gaap Goodwill
Goodwill
1679978 usd
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 us-gaap Inventory Net
InventoryNet
usd
CY2023Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
usd
CY2024Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
usd
us-gaap Repayments Of Debt
RepaymentsOfDebt
usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
usd
CY2023 us-gaap Asset Impairment Charges
AssetImpairmentCharges
usd
CY2023 mssv Derivative Instrument Additions
DerivativeInstrumentAdditions
usd
mssv Derivative Instrument Additions
DerivativeInstrumentAdditions
usd
mssv Derivative Instruments Conversions
DerivativeInstrumentsConversions
usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
usd
CY2023 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
usd
us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
usd
us-gaap Goodwill Impairment Loss Net Of Tax
GoodwillImpairmentLossNetOfTax
usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001760026

Files In Submission

Name View Source Status
0001213900-24-099836-index-headers.html Edgar Link pending
0001213900-24-099836-index.html Edgar Link pending
0001213900-24-099836.txt Edgar Link pending
0001213900-24-099836-xbrl.zip Edgar Link pending
ea0221540-10q_regenerative.htm Edgar Link pending
ea022154001ex31-1_regener.htm Edgar Link pending
ea022154001ex31-2_regener.htm Edgar Link pending
ea022154001ex32-1_regener.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
mssv-20240930.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
mssv-20240930_cal.xml Edgar Link unprocessable
mssv-20240930_def.xml Edgar Link unprocessable
mssv-20240930_lab.xml Edgar Link unprocessable
mssv-20240930_pre.xml Edgar Link unprocessable
ea0221540-10q_regenerative_htm.xml Edgar Link completed
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending